Clinical Trial Update: Safety Study of GS-5806 to Treat Respiratory Syncytial Virus (RSV) [Phase 1]

View source ↗

Summary

A Phase 1 safety study of GS-5806 for respiratory syncytial virus infection has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• GS-5806 (presatovir)

Snippet

Sponsor: Gilead Sciences | Conditions: Respiratory Syncytial Virus Infections | Phase 1 | Status: WITHDRAWN